News

MediGene to Present at Three Upcoming International Investor Conferences

Martinsried/Munich, September 5, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard, MDG) is pleased to announce that members of its Executive Management will present at three upcoming international investor conferences.


Rodman & Renshaw Annual Global Investment Conference, New York, USA
September 12, 2011, presentation scheduled for 4:30pm local time
Presentation to be given by Arnd Christ, CFO of MediGene AG


German Healthcare Conference, Zurich, Switzerland
September 13, 2011, presentation scheduled for 3:20pm local time
Presentation to be given by Dr. Frank Mathias, CEO of MediGene AG


German Equity Forum in Frankfurt/Main, Germany
November 22, 2011, presentation scheduled for 10:30am local time
Presentation to be given by Arnd Christ, CFO of MediGene AG


On each occasion the presentation will include a review of the Company and an update on recent business developments. Management will also be available for 1x1 meetings at each event. PDF versions and, if available, live and archived webcasts of Company presentations will be provided at www.medigene.com.


This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the forward-looking statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene® is a registered trademarks of MediGene AG. These trademarks may be owned or licensed in select locations only.

 

- ends -

 

MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. MediGene is the first German biotech company to have revenues from marketed products. It has various drug candidates in clinical development and possesses innovative platform technologies. MediGene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases.


Contact MediGene AG
Julia Hofmann, Kerstin Langlotz
Investor & Public Relations
Tel.: +49 - 89 - 85 65 - 33 01
Fax: +49 - 89 - 85 65 - 29 20
Email: investor@medigene.com